P. Madsen

发表

Small-molecule agonists for the glucagon-like peptide 1 receptor

Jeppe Sturis, Jarek Kostrowicki, Carsten Behrens, 2007, Proceedings of the National Academy of Sciences.

Endothelial cells of the human microvasculature express epidermal fatty acid-binding protein.

J. Saurat, P. Madsen, M. Pepper, 1997, Circulation research.

Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

D. Edgerton, A. Cherrington, Phillip E. Williams, 2019, JCI insight.

Peripherally delivered hepatopreferential insulin analog insulin‐406 mimics the hypoglycaemia‐sparing effect of portal vein human insulin infusion in dogs

A. Cherrington, Susanne Hostrup, J. Gregory, 2019, Diabetes, obesity & metabolism.

Molecular Engineering of Efficacious Mono-Valent Ultra-Long Acting Two-Chain Insulin-Fc Conjugates.

L. De Maria, Zhaosheng Lin, T. Pedersen, 2022, Journal of medicinal chemistry.

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing

T. Pedersen, R. Ribel‐Madsen, E. Nishimura, 2021, BMJ Open Diabetes Research & Care.

New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists

C. Behrens, L. B. Knudsen, C. L. Brand, 2007 .

Glucose-6-phosphatase catalytic enzyme inhibitors: synthesis and in vitro evaluation of novel 4,5,6,7-tetrahydrothieno[3,2-c]- and -[2,3-c]pyridines.

P. Madsen, N. Westergaard, A. Varming, 2000, Bioorganic & medicinal chemistry.

Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog

D. Edgerton, A. Cherrington, M. Scott, 2014, Diabetes.

Oligomer extended insulin-fc conjugates

Zhaosheng Lin, M. Münzel, J. T. Kodra, 2018 .

Advances in non-peptide glucagon receptor antagonists.

J. Holst, C. L. Brand, P. Madsen, 1999, Current pharmaceutical design.

Identification of two novel and potent competitive inhibitors of the glucose‐6‐phosphatase catalytic protein

P. Madsen, N. Westergaard, B. Andersen, 2002, Diabetes, obesity & metabolism.

Glucose-6-phosphatase inhibitors for the treatment of Type 2 diabetes

P. Madsen, N. Westergaard, 2001 .

Characterization of glycerol uptake and glycerol kinase activity in rat hepatocytes cultured under different hormonal conditions.

P. Madsen, N. Westergaard, K. Lundgren, 1998, Biochimica et biophysica acta.

Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.

J. Holst, J. D. de Jong, Michael D. Johnson, 2007, Bioorganic & medicinal chemistry letters.

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

A. Kuki, Michael D. Johnson, D. Murphy, 2002, Journal of medicinal chemistry.

Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

R. Carr, L. B. Knudsen, P. Madsen, 1998, Journal of medicinal chemistry.

New beta-alanine derivatives are orally available glucagon receptor antagonists.

C. Behrens, L. B. Knudsen, C. L. Brand, 2007, Journal of medicinal chemistry.

Human glucagon receptor antagonists based on alkylidene hydrazides.

A. Kuki, D. Murphy, A. Polinsky, 2002, Bioorganic & medicinal chemistry letters.

Tyrosine metabolism in users of oral contraceptives.

S. Møller, P. Madsen, B. Fjalland, 1995, Life sciences.

Increase in [Ca2+]i and subsequent insulin release from beta TC3-cells with the L-type Ca(2+)-channel activator, FPL 64176.

J. Gromada, J. Fuhlendorff, P. Madsen, 1997, Advances in experimental medicine and biology.

Imidazolines as efficacious glucose-dependent stimulators of insulin secretion.

P. Madsen, P. Jakobsen, HenrikSune Andersen, 2003, European journal of medicinal chemistry.

Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.

C. Behrens, L. B. Knudsen, E. Nishimura, 2009, Journal of medicinal chemistry.

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

C. Behrens, L. B. Knudsen, E. Nishimura, 2008, Journal of medicinal chemistry.

N,N-dibenzyl-N'-benzylidenehydrazines: potent competitive glucose-6-phosphatase catalytic enzyme inhibitors.

P. Madsen, N. Westergaard, P. Jakobsen, 2001, Bioorganic & medicinal chemistry letters.

Synthesis of substituted 10,11‐dihydro‐5H‐dibenz[b,f]azepines; key synthons in syntheses of pharmaceutically active compounds

J. Lau, P. Madsen, K. Andersen, 1999 .

Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans.

H. H. Refsgaard, T. Porsgaard, E. Nishimura, 2021, Journal of medicinal chemistry.

Molecular engineering of safe and efficacious oral basal insulin

E. Johansson, H. H. Refsgaard, U. Ribel, 2020, Nature Communications.

Insuline monocatenaire pegylee

P. Madsen, T. Kjeldsen, T. Tagmose, 2006 .

Synthesis of [3H]FPL 64176, a potent calcium channel activator

C. Foged, P. Madsen, 1994 .

Commemorating insulin's centennial: engineering insulin pharmacology towards physiology.

J. Sturis, T. Hoeg-Jensen, H. Haahr, 2021, Trends in pharmacological sciences.

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320.

H. H. Refsgaard, M. Münzel, L. Hovgaard, 2020, Journal of medicinal chemistry.

Synthesis of Substituted 10,11‐Dihydro‐5H‐dibenz[b,f]azepines; Key Synthons in Syntheses of Pharmaceutically Active Compounds.

J. Lau, P. Madsen, K. Andersen, 1999 .